117 related articles for article (PubMed ID: 23767831)
21. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
22. Advanced endometrial cancer with serous metastasis in a 17-year-old.
Cohn DE; Resnick KE; Ramirez NC; Morrison CD
Gynecol Oncol; 2006 May; 101(2):356-9. PubMed ID: 16499956
[TBL] [Abstract][Full Text] [Related]
23. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.
Trudel D; Labbé DP; Araya-Farias M; Doyen A; Bazinet L; Duchesne T; Plante M; Grégoire J; Renaud MC; Bachvarov D; Têtu B; Bairati I
Gynecol Oncol; 2013 Nov; 131(2):357-61. PubMed ID: 23988418
[TBL] [Abstract][Full Text] [Related]
24. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
Amant F; Cadron I; Fuso L; Berteloot P; de Jonge E; Jacomen G; Van Robaeys J; Neven P; Moerman P; Vergote I
Gynecol Oncol; 2005 Aug; 98(2):274-80. PubMed ID: 15972232
[TBL] [Abstract][Full Text] [Related]
25. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
[TBL] [Abstract][Full Text] [Related]
26. Molecular targets and targeted therapeutics in endometrial cancer.
Weigelt B; Banerjee S
Curr Opin Oncol; 2012 Sep; 24(5):554-63. PubMed ID: 22581357
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
Covens AL; Filiaci V; Gersell D; Lutman CV; Bonebrake A; Lee YC
Gynecol Oncol; 2011 Feb; 120(2):185-8. PubMed ID: 21075433
[TBL] [Abstract][Full Text] [Related]
28. The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Peled Y; Levavi H; Krissi H; Weill Y; Sabah G; Eitan R
Am J Clin Oncol; 2013 Oct; 36(5):472-4. PubMed ID: 22706176
[TBL] [Abstract][Full Text] [Related]
29. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
30. Current treatment options for endometrial cancer.
Santin AD; Bellone S; O'Brien TJ; Pecorelli S; Cannon MJ; Roman JJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):679-89. PubMed ID: 15270671
[TBL] [Abstract][Full Text] [Related]
31. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Brunetto VL; VanLe L; Bell J; Walker JL; Lee RB
Gynecol Oncol; 2000 Aug; 78(2):212-6. PubMed ID: 10926805
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of leuprolide in advanced/recurrent endometrial cancer.
Covens A; Thomas G; Shaw P; Ackerman I; Osborne R; Lukka H; Carey M; Franssen E; Roche K
Gynecol Oncol; 1997 Jan; 64(1):126-9. PubMed ID: 8995560
[TBL] [Abstract][Full Text] [Related]
33. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
[TBL] [Abstract][Full Text] [Related]
34. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
35. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
36. A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Aoki D; Katsumata N; Nakanishi T; Kigawa J; Fujiwara K; Takehara K; Kamiura S; Hiura M; Hatae M; Sugiyama T; Ochiai K; Noda K
Jpn J Clin Oncol; 2011 Mar; 41(3):320-7. PubMed ID: 20974678
[TBL] [Abstract][Full Text] [Related]
37. Management of advanced-stage and recurrent endometrial cancer.
Ray M; Fleming G
Semin Oncol; 2009 Apr; 36(2):145-54. PubMed ID: 19332249
[TBL] [Abstract][Full Text] [Related]
38. An impressive response to pazopanib in a patient with metastatic endometrial carcinoma.
van der Steen MJ; de Waal YR; Westermann A; Tops B; Leenders W; Ottevanger PB
Neth J Med; 2016 Nov; 74(9):410-413. PubMed ID: 27905309
[TBL] [Abstract][Full Text] [Related]
39. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
40. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
